Journal of Antimicrobial Chemotherapy (2000) 46, 485-487
© 2000 The British Society for Antimicrobial Chemotherapy
Brief reports |
In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide
Department of Obstetrics and Gynaecology, School of Medicine, Gifu University, 40 Tsukasa-machi, Gifu City, Gifu 500-8705, Japan
The antifungal activity of FK463 against 72 recent clinical isolates of Candida albicans (24), Candida glabrata (17), Candida tropicalis (11), Candida krusei (8) and Candida parapsilosis (12) was compared with those of amphotericin B, fluconazole and itraconazole by means of a broth microdilution method specified by the National Committee for Clinical Laboratory Standards (NCCLS) document M27-A. The lowest drug concentration at which 90% of the population was inhibited (MIC90) of FK463 against C. albicans, C. glabrata, C. tropicalis, C. krusei and C. parapsilosis was 0.0156, 0.0156, 0.0313, 0.125 and 1 mg/L, respectively. FK463 exhibited broad-spectrum activity against clinically important Candida spp. (MIC range 
0.0039–2 mg/L), and its MICs for such fungi were lower than those of other antifungal agents tested. The minimum fungicidal concentrations for Candida spp. did not differ by more than two-fold from the MICs. Results from pre-clinical evaluations performed to date indicate that FK463 should be a potent parenteral antifungal agent.
* Corresponding author. Tel: +81-58-267-2631; Fax: +81-58-265-9006; E-mail: mikamo{at}cc.gifu-u.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Keirns, T. Sawamoto, M. Holum, D. Buell, W. Wisemandle, and A. Alak Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults Antimicrob. Agents Chemother., February 1, 2007; 51(2): 787 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Bennett Echinocandins for Candidemia in Adults without Neutropenia N. Engl. J. Med., September 14, 2006; 355(11): 1154 - 1159. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Olson, J. P. Adler-Moore, P. J. Smith, and R. T. Proffitt Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin Antimicrob. Agents Chemother., December 1, 2005; 49(12): 4895 - 4902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Seibel, C. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, J. Keirns, W. M. Lau, D. P. Facklam, D. N. Buell, et al. Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3317 - 3324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hiemenz, P. Cagnoni, D. Simpson, S. Devine, N. Chao, J. Keirns, W. Lau, D. Facklam, and D. Buell Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1331 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ninomiya, H. Mikamo, K. Tanaka, K. Watanabe, and T. Tamaya Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice J. Antimicrob. Chemother., April 1, 2005; 55(4): 587 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L Carver Micafungin Ann. Pharmacother., October 1, 2004; 38(10): 1707 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takakura, N. Fujihara, T. Saito, T. Kudo, Y. Iinuma, S. Ichiyama, and the Japan Invasive Mycosis Surveillance Study Grou National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin J. Antimicrob. Chemother., February 1, 2004; 53(2): 283 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Arikan, P. Yurdakul, and G. Hascelik Comparison of Two Methods and Three End Points in Determination of In Vitro Activity of Micafungin against Aspergillus spp. Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2640 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Luque, K. V. Clemons, and D. A. Stevens Efficacy of Micafungin Alone or in Combination against Systemic Murine Aspergillosis Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1452 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laverdiere, D. Hoban, C. Restieri, and F. Habel In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients J. Antimicrob. Chemother., July 1, 2002; 50(1): 119 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Petraitis, R. Petraitiene, A. H. Groll, K. Roussillon, M. Hemmings, C. A. Lyman, T. Sein, J. Bacher, I. Bekersky, and T. J. Walsh Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1857 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Groll, D. Mickiene, V. Petraitis, R. Petraitiene, K. H. Ibrahim, S. C. Piscitelli, I. Bekersky, and T. J. Walsh Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3322 - 3327. [Abstract] [Full Text] [PDF]
|
|